(3RB) Reckitt Benckiser - Ratings and Ratios
Exchange: XETRA • Country: United Kingdom • Currency: EUR • Type: Common Stock • ISIN: GB00B24CGK77
3RB: Health, Hygiene, Nutrition, Personal Care, Vitamins, Cleaning, Baby Food
Reckitt Benckiser Group plc (XETRA:3RB) is a leading global consumer goods company specializing in health, hygiene, and nutrition products. With a diverse portfolio of trusted brands, the company addresses essential consumer needs across multiple categories. Its product range includes germ protection solutions under Dettol; intimate wellness products under Durex and KY; and over-the-counter medications such as Biofreeze, Gaviscon, Mucinex, Nurofen, and Strepsils. The company also offers personal care products like Clearasil and Veet; vitamins and supplements under Airborne, Move Free, and Neuriva; and disinfectant products under Finish, Harpic, and Lysol. Additionally, Reckitt Benckiser provides nutrition solutions for infants and young children through brands like Enfamil and Nutramigen. Founded in 1819 and headquartered in Slough, UK, the company has a long-standing history of innovation and has expanded its reach through strategic acquisitions, including the purchase of Mead Johnson Nutrition in 2017. Reckitt Benckiser is recognized for its commitment to research and development, with a focus on creating high-quality, science-driven products. The company also emphasizes sustainability, aiming to improve access to hygiene, sanitation, and nutrition globally.
Additional Sources for 3RB Stock
3RB Stock Overview
| Market Cap in USD | 42,481m |
| Sector | Consumer Defensive |
| Industry | Household & Personal Products |
| GiC Sub-Industry | Personal Care Products |
| IPO / Inception |
3RB Stock Ratings
| Growth Rating | -12.2 |
| Fundamental | 61.9 |
| Dividend Rating | 57.6 |
| Rel. Strength | -9.69 |
| Analysts | - |
| Fair Price Momentum | 48.17 EUR |
| Fair Price DCF | 87.54 EUR |
3RB Dividends
| Dividend Yield 12m | 4.91% |
| Yield on Cost 5y | 4.16% |
| Annual Growth 5y | 2.37% |
| Payout Consistency | 98.4% |
3RB Growth Ratios
| Growth Correlation 3m | -79.1% |
| Growth Correlation 12m | 84.6% |
| Growth Correlation 5y | -66.8% |
| CAGR 5y | -2.81% |
| CAGR/Max DD 5y | -0.07 |
| Sharpe Ratio 12m | 0.54 |
| Alpha | 8.75 |
| Beta | 0.148 |
| Volatility | 30.16% |
| Current Volume | 2.2k |
| Average Volume 20d | 6.2k |
As of May 09, 2025, the stock is trading at EUR 57.90 with a total of 2,226 shares traded.
Over the past week, the price has changed by -0.07%, over one month by +2.83%, over three months by -5.51% and over the past year by +13.52%.
Yes, based on ValueRay Fundamental Analyses, Reckitt Benckiser (XETRA:3RB) is currently (May 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 61.90 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of 3RB as of May 2025 is 48.17. This means that 3RB is currently overvalued and has a potential downside of -16.8%.
Reckitt Benckiser has no consensus analysts rating.
According to ValueRays Forecast Model, 3RB Reckitt Benckiser will be worth about 52 in May 2026. The stock is currently trading at 57.90. This means that the stock has a potential downside of -10.14%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 52 | -10.1% |